SCHEMBL5249809

SCHEMBL5249809

Cc1cc(O)c2cccc(Br)c2n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.57
GAA P10253 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.50
KDM4E B2RXH2 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
METAP2 P50579 1/20 0.42
ALDH1A1 P00352 2/20 0.41
CD38 P28907 1/20 0.40
NR4A2 P43354 1/20 0.40
ENPP3 O14638 1/20 0.37
ENPP1 P22413 1/20 0.37
TP53 P04637 1/20 0.37
KMT2A Q03164 2/20 0.37
OPRK1 P41145 1/20 0.37
NQO2 P16083 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
HRH4 Q9H3N8 1/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
MYC P01106 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3498769 0.81 MAPT (0.42) MAPTGAASMN1; SMN2KDM4ETDP1
SCHEMBL6215236 0.81 TP53 (0.54) MAPTGAASMN1; SMN2KDM4ETDP1
SCHEMBL2284354 0.81 KDM4E (0.62) MAPTGAASMN1; SMN2KDM4ETDP1
SCHEMBL2943672 0.79 GAA (0.48) MAPTGAASMN1; SMN2KDM4ETDP1
SCHEMBL1026984 0.79 NR4A2 (0.65) MAPTKDM4ETDP1METAP2CD38
SCHEMBL22084269 0.79 KDM4E (0.42) MAPTGAAKDM4ETDP1METAP2
SCHEMBL11692297 0.79 KDM4E (0.69) MAPTGAASMN1; SMN2KDM4ETDP1
SCHEMBL1563032 0.79 METAP2 (0.55) MAPTGAASMN1; SMN2KDM4ETDP1
SCHEMBL30018381 0.79 EPRS1 (0.43) MAPTGAASMN1; SMN2KDM4EMETAP2
SCHEMBL439824 0.79 NR4A2 (0.65) MAPTGAASMN1; SMN2KDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1299378-B1 TETRAHYDROPYRIDINO OR PIPERIDINO HETEROCYCLIC DERIVATIVES TAISHO PHARMACEUTICAL CO LTD (JP) 2007-02-14 EP disclosed
US-7160900-B2 Tetrahydropyridino or piperidino heterocyclic derivatives TAISHO PHARMACEUTICAL CO., LTD. (JP) 2007-01-09 US disclosed
EP-0966442-B1 QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONIST ACTIVITY DUPHAR INT RES (NL) 2006-12-20 EP disclosed
CN-1260225-C Tetrahydropyridyl or piperidinyl heterocyclic derivatives TAISHO PHARMACEUTICAL CO LTD (JP) 2006-06-21 CN disclosed
US-6852732-B2 Tetrahydropyridino or piperidino heterocylic derivatives TAISHO PHARMACEUTICAL CO., LTD. (JP) 2005-02-08 US disclosed
US-20050009874-A1 Tetrahydropyridin or piperidino heterocyclic derivatives TAISHO PHARMACEUTICAL CO., LTD. 2005-01-13 US disclosed
CN-1535968-A Tetrahydro pyridyl or pyridyl heterocycle derivative ������ҩ��ʽ���� 2004-10-13 CN disclosed
US-20040034061-A1 Tetrahydropyridino or piperidino heterocylic derivatives TAISHO PHARMACEUTICAL CO., LTD. (JP) 2004-02-19 US disclosed
EP-1299378-A4 TETRAHYDROPYRIDINO OR PIPERIDINO HETEROCYCLIC DERIVATIVES TAISHO PHARMACEUTICAL CO LTD (JP) 2004-01-28 EP disclosed
CN-1439001-A Tetrahydropyridyl or piperidinyl heterocyclic derivatives TAISHO PHARMACEUTICAL CO LTD (JP) 2003-08-27 CN disclosed
EP-1299378-A1 TETRAHYDROPYRIDINO OR PIPERIDINO HETEROCYCLIC DERIVATIVES Taisho Pharmaceutical Co. Ltd. (JP) 2003-04-09 EP disclosed
US-6350750-B1 TREATMENT OF STRESS-RELATED DISORDERS; ARYLATION WITH BORONIC ACID DERIVATIVE, AMINATION DUPHAR INTERNATIONAL RESEARCH B.V. (NL) 2002-02-26 US disclosed
WO-2002002549-A1 TETRAHYDROPYRIDINO OR PIPERIDINO HETEROCYCLIC DERIVATIVES TAISHO PHARMACEUTICAL CO., LTD. (JP) 2002-01-10 WO disclosed
EP-0966442-A1 QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONIST ACTIVITY DUPHAR INTERNATIONAL RESEARCH B.V (NL) 1999-12-29 EP disclosed
WO-1999012908-A1 QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONIST ACTIVITY DUPHAR INTERNATIONAL RESEARCH B.V. (NL) 1999-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009874-A1 Tetrahydropyridin or piperidino heterocyclic derivatives CRHR1, CRHR2, VIPR1 MAPT 3511/4885GAA 3257/4885SMN1; SMN2 3336/4885
US-20040034061-A1 Tetrahydropyridino or piperidino heterocylic derivatives CRHR1, CRHR2, AGTR1 MAPT 3323/4885GAA 3380/4885SMN1; SMN2 2496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.